- Home
- EDD vs SGHT Comparison
EDD vs SGHT Comparison
Compare EDD & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- SGHT
- Stock Information
- Founded
- EDD 2007
- SGHT 2011
- Country
- EDD United States
- SGHT United States
- Employees
- EDD N/A
- SGHT N/A
- Industry
- EDD Finance Companies
- SGHT Medical Specialities
- Sector
- EDD Finance
- SGHT Health Care
- Exchange
- EDD Nasdaq
- SGHT Nasdaq
- Market Cap
- EDD 304.3M
- SGHT 304.4M
- IPO Year
- EDD N/A
- SGHT 2021
- Fundamental
- Price
- EDD $4.78
- SGHT $4.23
- Analyst Decision
- EDD
- SGHT Buy
- Analyst Count
- EDD 0
- SGHT 6
- Target Price
- EDD N/A
- SGHT $7.10
- AVG Volume (30 Days)
- EDD 254.3K
- SGHT 227.8K
- Earning Date
- EDD 01-01-0001
- SGHT 11-07-2024
- Dividend Yield
- EDD 7.52%
- SGHT N/A
- EPS Growth
- EDD N/A
- SGHT N/A
- EPS
- EDD N/A
- SGHT N/A
- Revenue
- EDD N/A
- SGHT $79,543,000.00
- Revenue This Year
- EDD N/A
- SGHT $3.39
- Revenue Next Year
- EDD N/A
- SGHT $11.42
- P/E Ratio
- EDD N/A
- SGHT N/A
- Revenue Growth
- EDD N/A
- SGHT N/A
- 52 Week Low
- EDD $4.22
- SGHT $1.58
- 52 Week High
- EDD $4.95
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- EDD 46.40
- SGHT 31.46
- Support Level
- EDD $4.78
- SGHT $4.46
- Resistance Level
- EDD $4.78
- SGHT $5.19
- Average True Range (ATR)
- EDD 0.07
- SGHT 0.30
- MACD
- EDD 0.01
- SGHT -0.07
- Stochastic Oscillator
- EDD 73.68
- SGHT 2.31
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.